Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDATOR: Pre‑emptive Daratumumab Therapy for MRD Reappearance or Biochemical Relapse in Multiple Myeloma
2017-003253-41Phase 2Active
- Sponsor
- Polish Myeloma Consortium
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Polish Myeloma Consortium. Started Aug 2018; status: active.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-003253-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003253-41.